Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose Finding Study to Evaluate the Efficacy and Safety of LIB003 in Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs LIB-003 (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2018 New trial record